Pulse Biosciences, Inc.

NASDAQ:PLSE

Medical - Instruments & Supplies

Healthcare
$45.83 +3.83%

+$0.97 today

Market cap
$3.37B
Beta
1.66
P/E (TTM)
-24.0
EPS (TTM)
-$1.10
52W Low $12.56High $28.53

Volume 0.33M

Average 0.31M

PLSE Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Pulse Biosciences, Inc.NASDAQ: PLSE

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $4.97M fell 4.2% year over year, ahead of the -15.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 160.1% from the prior quarter. Over 3 fiscal years it compounded at +60.5% a year.

Context

  • Stock-based compensation amounted to 6130.6% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -4.2% holds above the trailing-twelve-month pace of -15.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.97M+160.1% QoQ
Last fiscal yearDec 2025
$21.46M+57.9% YoY
LTMJun 2026
$17.47M-15.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.2%——
1 year+57.9%——
3-year CAGR+60.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
21.46M USD
Year-over-year change
+57.9%
4-year CAGR
+10.1%

Stock-Based Compensation vs competitors

How PLSE compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.4% is the 6th highest of 11, against a peer median of -9.6%.
  • Stock-based compensation amounts to 1474.4% of revenue for PLSE, versus a peer median of 18.7%.
PLSE Competitors
Stock-Based Compensation for PLSE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$118.47M USD-23.8%—17.6%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$45.65M USD+1845.1%—54.5%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$34.27M USD+82.5%+146.7%1800.0%
STAASTAAR Surgical CompanyLTM Apr 2026$29.4M USD+9.3%+14.5%10.1%
BBNXBeta Bionics, Inc.LTM Mar 2026$18.99M USD+142.5%+39.0%17.2%
PLSEPulse Biosciences, Inc.LTM Jun 2026$17.47M USD-15.4%+60.5%1474.4%
ATAIAtai Beckley Inc.LTM Jun 2026$16.18M USD-17.0%—361.7%
NKTRNektar TherapeuticsLTM Jun 2026$11.99M USD-31.8%-39.6%22.0%
OPKOPKO Health, Inc.LTM Mar 2026$10.83M USD-2.2%-16.7%1.9%
LFMDLifeMD, Inc.LTM Mar 2026$7.95M USD-35.1%-8.6%3.6%
IMTXImmatics N.V.LTM Mar 2026€7.38M EUR-44.8%—19.8%
Peer median (excluding PLSE) —-9.6%+3.0%18.7%

Competitors are the stored peer set for PLSE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.66M)(58.51M)(42.21M)(53.59M)(72.78M)
Depreciation & Amortization1.15M1.36M1.21M1.18M1.07M
Deferred Income Tax00000
Stock-Based Compensation14.6M5.19M7.18M13.59M21.46M
Change in Working Capital(6.2M)(3.72M)768K2.47M(5.02M)
Accounts Receivables(61K)20K109K48K(274K)
Inventory(5.82M)(2.65M)00(136K)
Accounts Payables1.16M(1.3M)263K(201K)1.13M
Other Working Capital(1.47M)221K396K2.63M(5.74M)
Other Non-Cash Items13K8.66M13K6K1.15M
Operating Cash Flow(54.1M)(47.01M)(33.04M)(36.34M)(54.12M)
Capital Expenditures(437K)(401K)(121K)(125K)(315K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments8M0000
Other Investing Activities0000(20K)
Investing Cash Flow7.56M(401K)(121K)(125K)(335K)
Debt Repayment407K65M000
Common Stock Issued56.7M14.86M16.39M59.65M17.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities62.51M75K(6K)50.49M0
Financing Cash Flow62.69M79.94M16.39M110.14M17.15M
Effect of Forex Changes00000
Net Change in Cash16.15M32.53M(16.77M)73.67M(37.3M)
Free Cash Flow(54.53M)(47.41M)(33.16M)(36.47M)(54.44M)

Pulse Biosciences, Inc.

NASDAQ:PLSE

Intrinsic Alpha fair value

Locked

Current Price

$45.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.